RxDoctor Payments Data

Andrew Ropp, MD

Family Medicine · Santa Fe, NMNPI 1619087582

Payments from drug & device makers

$423in general payments, 2019–2025

Across 23 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$118
  • Pfizer$95
  • AstraZeneca$84
  • Novo Nordisk$45
  • Merck$38
  • Genentech USA, Inc.$16
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$423 in reported general payments places this provider in the 70th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$219,625
Medicare patients
853
Services billed
2,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide33$60,486
TrulicityDulaglutide26$40,119
OzempicSemaglutide21$34,798
EliquisApixaban23$34,156
JardianceEmpagliflozin18$28,696
JanuviaSitagliptin Phosphate17$26,320
Tresiba Flextouch U-200Insulin Degludec14$16,879
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$12,696
Nurtec OdtRimegepant Sulfate12$11,521
Tresiba Flextouch U-100Insulin Degludec16$7,254
Atorvastatin Calcium499$6,351
SymbicortBudesonide/Formoterol Fumarate21$5,834
Testosterone18$3,635
Losartan Potassium267$3,397
Levothyroxine Sodium243$2,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$45$95,28454 claims
PfizerEliquis, Nurtec Odt$95$45,67835 claims
Lilly USA, LLCTrulicity$13$40,11926 claims
Boehringer IngelheimJardiance$14$28,69618 claims
MerckJanuvia$38$26,32017 claims
AstraZenecaSymbicort$84$5,83421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →